More than 10,000 patients Licensed US practitioners 100% Online

Tirzepatide works on several systems at once, which is why its effects show up in both appetite and blood sugar.

It reduces appetite signaling in the brain. GLP-1 and GIP receptors sit in the hypothalamus and brainstem, which regulate hunger and satiety. Activating them lowers the drive to eat and reduces time spent thinking about food.

It slows gastric emptying. Food leaves the stomach more slowly, so you feel full sooner and stay full longer. This is strongest in the first weeks at a new dose and softens over time.

It improves the insulin response to food. Tirzepatide increases insulin release in a glucose-dependent way, acting when blood sugar is elevated and easing off when it is not. It also suppresses glucagon, which tells the liver to release stored glucose.

It improves insulin sensitivity. GIP receptor activity in fat tissue appears to affect how the body handles lipids and how sensitive tissues are to insulin, though the mechanism is still being characterized.

The result is a smaller appetite, earlier fullness, steadier blood sugar and fewer of the swings that drive snacking. Most patients notice reduced appetite within the first week. Changes on the scale build more gradually over the first one to two months.

Every figure above is a starting price. Tirzepatide starts at $249 a month and what you pay depends on the plan and dose your practitioner prescribes, so treat $249 as the entry point rather than a flat rate across every dose. The price covers the clinician review, your personalized treatment plan, labs, ongoing care and delivery, with no separate consultation fee.

There are no long-term contracts, and you can pause, switch or cancel anytime. Read that alongside the refund policy: the first two (2) months of any treatment plan are strictly non-refundable under any circumstances, and cancelling stops future billing cycles rather than refunding charges already processed. Budget for two months before you start.

Zepbound® is Eli Lilly's tirzepatide product for chronic weight management. Society does not supply it, and it is named on this page only to identify the molecule.

Questions

The evaluation takes two minutes, there is no insurance to fight and no in-person visit to book.

* Individual results may vary, and not all patients will qualify for treatment. Always consult a licensed healthcare provider before starting or modifying any medical treatment.

Society facilitates access to consultations with independent, licensed healthcare providers who evaluate each patient and determine eligibility for treatment. Prescription products require an online medical evaluation. Medications are prescribed by independent physicians and dispensed by licensed U.S. pharmacies or a patient's preferred pharmacy. Only a qualified healthcare provider can determine whether a treatment is appropriate for an individual's specific medical needs.
Providers are licensed in the state where the patient is located at the time of consultation, and availability may vary by state.
Society's services are intended for individuals 18 years of age or older. Age verification may be required as part of the intake process.
‍Society partners with licensed U.S. pharmacies. Certain treatments may include compounded medications, which are not FDA-approved and have not been evaluated by the Food and Drug Administration for safety, efficacy, or quality. Compounded medications may be prescribed by a healthcare provider based on individual patient needs or during periods of drug shortages. FDA-approved GLP-1 medications—such as Ozempic® (semaglutide), Wegovy® (semaglutide), and Zepbound® (tirzepatide)—are not compounded. Society is not affiliated with, endorsed by, or sponsored by the manufacturers of these products. All trademarks and brand names belong to their respective owners.
GLP-1–based treatments may carry risks, including the potential for thyroid C-cell tumors. These medications should not be used by individuals with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Please consult a healthcare provider for complete prescribing and safety information.
Prescription medications are dispensed only when determined appropriate by a licensed healthcare provider following an online medical evaluation. No prescription is guaranteed, and treatment decisions are made solely at the prescriber's clinical discretion.
Statements on this website have not been evaluated by the Food and Drug Administration and are not intended to diagnose, treat, cure, or prevent any disease. Images shown are for illustrative purposes only; actual product appearance may vary.